GMAB ▲ +0.8% - Genmab A/S
$GMAB Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting
04-NOV-2026 09:03 AM ET
Share this post
More filings for $GMAB
GMAB ▲ +34.1% - Genmab A/SOct 28, 2026GMAB ▲ +25.5% - Genmab A/SOct 28, 2026GMAB ▲ +19.6% - Genmab A/SOct 28, 2026GMAB ▲ +16.1% - Genmab A/SOct 28, 2026GMAB ▲ +16.1% - Genmab A/SOct 28, 2026GMAB ▲ +3.5% - Genmab A/SOct 26, 2026
View full $GMAB filing history →💬 Comments
Loading comments…
Leave a comment